Paula Cobb

Paula has led strategy and operations for more than 15 programs advancing them through meaningful milestones ranging from discovery to clinic and approvals to launches. She spent most of her career at Biogen in roles of increasing responsibility across new product planning, program management, and franchise management, culminating as Senior Vice President of the Rare Disease group. In this role, she managed a portfolio of clinical and commercial assets across hemophilia, spinal muscular atrophy, and other rare genetic diseases with annual revenues of over $750 million. More recently, Paula was the Chief Operating Officer of gene therapy company, Decibel Therapeutics, and a Board member of gene therapy company, Nightstar Therapeutics, until its acquisition by Biogen in 2019 for $800 million. Paula is a current Board member of Prothena. She received her B.A. from Amherst College and her M.B.A. from Harvard University.